















The First Korean Case of *NUP98-NSD1* and a Novel *SNRK-ETV6* Fusion in a Pediatric Therapy-related Acute Myeloid Leukemia Patient Detected by Targeted RNA Sequencing

Ha Jin Lim , M.D.^{1*}, Jun Hyung Lee , M.D.^{1*}, Young Eun Lee , M.S.^{1,2}, Hee-Jo Baek , M.D.³, Hoon Kook , M.D.³, Ju Heon Park , M.D.¹, Seung Yeob Lee , M.D.¹, Hyun-Woo Choi , M.D.¹, Hyun-Jung Choi , M.D.¹, Seung-Jung Kee , M.D.¹, Jong Hee Shin , M.D.¹, and Myung Geun Shin , M.D.^{1,2}

¹Department of Laboratory Medicine, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea; ²Brain Korea 21 Plus Project, Chonnam National University Medical School, Gwangju, Korea; ³Department of Pediatrics, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, Korea

Dear Editor,

Targeted RNA-sequencing (RNA-seq) using next-generation sequencing (NGS) technology is a highly accurate method for selecting and sequencing specific transcripts of interest [1]. We routinely applied a customized targeted RNA-seq system during the diagnostic phase of hematologic malignancies. Our system detected the first Korean case of *NUP98-NSD1* and a novel *SNRK-ETV6* fusion with therapy-related acute myeloid leukemia (t-AML) showing a dismal clinical course. *NUP98-NSD1* accounts for approximately 4% of pediatric AML cases and shows a poor prognosis [2, 3]. It could be created by a cryptic t(5;11)(q35;p15.5) and exerts a leukemogenic function by binding near the *HOX* locus and *MEIS1* to increase expression via histone modifications [4]. The Institutional Review Board of Chonnam National University Hwasun Hospital (CNUHH), Hwasun, Korea (CNUHH-2020-091) approved this study and granted a waiver of consent due to its retrospective nature. This report highlights the role of high-throughput parallel targeted RNA-seq in enhancing the diagnostic yield of hematologic malignancies.

In April 2020, a 14-year-old girl visited the outpatient clinic of CNUHH 1.5 years and 1.9 years after a matched unrelated peripheral blood stem cell transplantation and initial diagnosis of AML, respectively, for a follow-up bone marrow (BM) examination. At initial diagnosis, the Korean AML 2012 regimen (double-induction strategy with idarubicin or mitoxantrone plus cytarabine, followed by consolidation therapy with cytarabine and etoposide) was administered and complete remission was achieved 28 days after the second induction. The laboratory findings showed a leukocyte count of $3.1 \times 10^9/L$, absolute neutrophil count of $0.58 \times 10^9/L$, hemoglobin of 114 g/L, and platelet count of $37 \times 10^9/L$. BM aspirates revealed 28% leukemic blasts corresponding to French-American-British (FAB) type M2. The BM karyotype was 45,XX,add(3)(p25),del(5)(q?),-12,add(12)(p13)[8]/46,XY[12], and the multiplex reverse transcription (RT)-PCR (HemaVision kit; DNA Technology, Aarhus, Denmark) finding was negative.

Targeted RNA-seq (HEMEaccuTest RNA; NGeneBio, Seoul, Korea) of the BM sample using STAR-Fusion (ver 1.8.1) and

Received: June 29, 2020
Revision received: October 5, 2020
Accepted: January 4, 2021

Corresponding author: Myung-Geun Shin, M.D.
Department of Laboratory Medicine, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun-eup, Hwasun-gun, Jeollanam-do 58128, Korea
Tel: +82-61-379-7950, Fax: +82-61-379-7984,
E-mail: mgshin@chonnam.ac.kr
*These authors equally contributed to this study.



© Korean Society for Laboratory Medicine

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<https://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

FusionCatcher (ver 1.20) revealed *NUP98-NSD1* and a novel *SNRK-ETV6* fusion, which were confirmed by direct sequencing (Fig. 1). DESeq2 (ver 1.18.1) analysis showed that *WT1*, *ERG*, and *BAALC* expression increased 7.1, 5.6, and 4.1- \log_2 -fold, respectively, compared with 14 normal controls (Table 1). An additional tier II variant of *WT1*, NM_024426.3:c.1142C>A (p.Ser381*), and three tier III variants were detected by FreeBayes (ver 1.3.1) [5]. Further targeted DNA NGS (HEMEaccuTest DNA) confirmed the variants in targeted RNA-seq and additionally detected a tier II variant of *KRAS*, NM_033360.4:c.38G>A (p.Gly13Asp), and five tier III variants. However, no significant variant of *FLT3*, including *FLT3-ITD*, was detected. Donor lymphocyte infusion (DLI) was conducted on day 7 after the diagnosis; however, the BM blasts increased to 88% on day 29. The combination of fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy was started on day 35 and the BM blasts decreased to <5% on day 71 with sustained thrombocytopenia; however, the condition repeatedly relapsed on day 134 and the patient expired on day 223.

NUP98-NSD1⁺ AML is characterized by frequent FAB-type

M4/M5, a normal karyotype, and *HOXA/B* upregulation [2]. Further, *NUP98-NSD1* is mutually exclusive with other type II variants, but often co-occurs with type I variants such as *FLT3-ITD* or *WT1* variants [2, 3]. *FLT3-ITD* is the most common variant in *NUP98-NSD1*⁺ AML (unlike our case), and its prognosis is dismal. Recent studies showed the promising therapeutic effects of dasatinib and navitoclax combination therapy and preemptive DLI based on minimal residual disease for *NUP98-NSD1*⁺/*FLT3-ITD*⁺ AML [6, 7]. Regarding the novel *SNRK-ETV6* fusion, the defect in *ETV6* is pathogenic in hematologic malignancies caused by rearrangement or deletions [8]. However, the partner *SNRK* gene defect at 3p22.1 has rarely been studied in hematologic malignancies but reportedly impacts hematopoietic cell proliferation and differentiation [9]. Further studies are needed to clarify the role of this novel fusion. This case also meets the criteria of t-AML, representing del(5q) with a complex karyotype and prior cytotoxic chemotherapy; both *NUP98*- and *ETV6*- rearrangements were reported in t-AMLs [10]. Additionally, the patient has a variant in *TP53* (rs1042522), known to increase the risk of developing therapy-related myeloid neoplasms. Owing to




Fig. 1. Schematic representation of the *NUP98-NSD1* (A–C) and novel *SNRK-ETV6* (D–F) gene fusions and proteins. (A) Integrative genomics viewer (IGV) image showing the *NUP98-NSD1* breakpoints with 171 supporting junction read counts. (B) Direct sequencing confirmed the identical breakpoint causing an in-frame fusion of *NUP98-NSD1*. (C) The predicted fusion protein translated from the *NUP98-NSD1* transcript based on a merged sequence produced by STAR-Fusion (ver 1.8.1), which contains domains similar to a previous report [2] but is shorter. (D) IGV image showing the novel *SNRK-ETV6* fusion breakpoints with 484 supporting junction read counts. (E) Direct sequencing confirmed the identical breakpoint causing a novel in-frame fusion of *SNRK-ETV6*. (F) The predicted fusion protein translated from the *SNRK-ETV6* transcript based on the merged sequence produced by STAR-Fusion (ver 1.8.1).

Table 1. Morphological, phenotypic, cytogenetic, and molecular characteristics of the initial and present phase of the case

	Initial phase		Present phase [†]	
	Finding	Method	Finding	Method
WHO classification	AML, NOS	t-AML		
FAB, type	M2	Microscopic observation	M2	Microscopic observation
Expressed marker	CD33, CD34, CD117, HLA-DR, and MPO	Immunophenotyping or cytochemical stain	CD33, CD34, CD117, and MPO	Immunophenotyping or cytochemical stain
Karyotype	46,XX[20]	Karyotyping	45,XX,add(3)(p25),del(5)(q?),-12,add(12)(p13)[8]/46,XY[12]	Karyotyping
Gene fusion	Negative	Multiplex RT-PCR	NUP98-NSD1 SNRK-ETV6	Targeted RNA-seq
Upregulated gene	WT1	Real-time PCR*	WT1 ERG BAALC TP63 FGFR3 CCND1 CRLF2	Targeted RNA-seq
Variants	NM_024426.3(WT1):c.1142C>A (p.Ser381*) [†]	DNA NGS	NM_024426.3(WT1):c.1142C>A (p.Ser381*) [†]	Targeted RNA-seq and DNA NGS
	NM_016320.4(NUP98):c.3557T>G (p.Leu1186Trp)	47.15	NM_001166693.2(AFF1):c.1021A>G (p.Lys341Glu) [§]	40.58
	NM_006197.3(PCMT1):c.4148A>G (p.Asp1383Gly)	47.50	NM_016320.4(NUP98):c.3557T>G (p.Leu1186Trp)	10.45
	NM_033360.4(KRAS):c.38G>A (p.Gly13Asp) [†]	17.39	NM_006197.3(PCMT1):c.4148A>G (p.Asp1383Gly)	9.47
	NM_002834.3(PTPN11):c.227A>C (p.Glu76Ala)	3.89	NM_033360.4(KRAS):c.38G>A (p.Gly13Asp) [†]	10.79
			NM_018036.6(ATG2B):c.1586C>T (p.Thr529Met) [§]	DNA NGS
			NM_000051.3(ATM):c.2117C>T (p.Ser706Leu)	38.94
			NM_022552.4(DNMT3A):c.920C>T (p.Pro307Leu)	10.85
			NM_000215.3(UAK3):c.2062A>T (p.Ile688Phe) [§]	3.11
			NM_017617.5(NOTCH1):c.4627G>A (p.Gly1543Arg) [§]	34.82
				35.32

*Using the WT1 ProfileQuant kit (Ipsogen, Marseille, France). [†]Tier II variants classified by the grading system according to the levels of evidence required to determine significance [5]. [‡]Increased gene expression was defined as a > 2-log₂-fold increase compared with 14 normal controls. HOXA/B expression could not be determined in the present case owing to the lack of a target RNA-seq panel. [§]Variants with a VAF of approximately 35% to 40% that could possibly be donor-derived germline variants rather than clonal evolution. Abbreviations: FAB, French-American-British; AML, acute myeloid leukemia; NOS, not otherwise specified; VAF, variant allele frequency; RT-PCR, reverse transcription-PCR; NGS, next-generation sequencing; t-AML, therapy-related AML; RNA-seq, RNA-sequencing.

the retrospective nature of this study, the *NUP98-NSD1* and *SNRK-ETV6* status at the initial diagnostic phase could not be ascertained.

Compared with previous studies using multiple diagnostic methods to characterize *NUP98-NSD1*⁺ AML [2], the advantage of the present case was the use of RNA-seq, representing a simplified diagnostic step for gene fusion, expression, and gene variant analyses. Additionally, this system might help uncover novel genetic characteristics in leukemias in future larger-scale studies.

AUTHOR CONTRIBUTIONS

Lim HJ and Lee JH conceived and designed the study and collected and analyzed the data; Baek HJ and Kook H contributed to the data; Lim HJ and Shin MG wrote the final manuscript; Lee YE, Park JH, Lee SY, Choi HW, Choi HJ, Kee SJ, and Shin JH participated in coordination and discussion. All authors have accepted their responsibility for the entire content of this manuscript and approved the submission.

CONFLICTS OF INTEREST

No potential conflicts of interest relevant to this article were reported.

RESEARCH FUNDING

This research was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (MSIT) and the Ministry of Health and Welfare (MOHW) (NRF-2019M3E5D1A02067952).

ORCID

Ha Jin Lim	https://orcid.org/0000-0003-2436-5007
Jun Hyung Lee	https://orcid.org/0000-0002-8682-3694
Young Eun Lee	https://orcid.org/0000-0003-2700-3087
Hee-Jo Baek	https://orcid.org/0000-0003-2301-9823
Hoon Kook	https://orcid.org/0000-0002-9135-5821

Ju Heon Park	https://orcid.org/0000-0002-6842-0234
Seung Yeob Lee	https://orcid.org/0000-0003-2851-1112
Hyun-Woo Choi	https://orcid.org/0000-0002-9438-1603
Hyun-Jung Choi	https://orcid.org/0000-0003-2901-5962
Seung-Jung Kee	https://orcid.org/0000-0001-9708-5837
Jong Hee Shin	https://orcid.org/0000-0001-9593-476X
Myung Geun Shin	https://orcid.org/0000-0002-0372-9185

REFERENCES

1. Zhong Y, Xu F, Wu J, Schubert J, Li MM. Application of next generation sequencing in laboratory medicine. *Ann Lab Med* 2021;41:25-43.
2. Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, Pratorcora M, Abbas S, Kuipers JE, et al. *NUP98/NSD1* characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct *HOX* gene expression pattern. *Blood* 2011;118:3645-56.
3. Niktoreh N, Walter C, Zimmermann M, von Neuhoff C, von Neuhoff N, Rasche M, et al. Mutated *WT1*, *FLT3-ITD*, and *NUP98-NSD1* fusion in various combinations define a poor prognostic group in pediatric acute myeloid leukemia. *J Oncol* 2019;2019:1609128.
4. Franks TM, McCloskey A, Shokirev MN, Benner C, Rathore A, Hetzer MW. Nup98 recruits the Wdr82-Set1A/COMPASS complex to promoters to regulate H3K4 trimethylation in hematopoietic progenitor cells. *Genes Dev* 2017;31:2222-34.
5. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn* 2017;19:4-23.
6. Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, et al. Dasatinib and navitoclax act synergistically to target *NUP98-NSD1*(+)/*FLT3-ITD*(+) acute myeloid leukemia. *Leukemia* 2019;33:1360-72.
7. Mitani Y, Hiwatari M, Seki M, Hangai M, Takita J. Successful treatment of acute myeloid leukemia co-expressing *NUP98/NSD1* and *FLT3/ITD* with preemptive donor lymphocyte infusions. *Int J Hematol* 2019;110:512-6.
8. De Braekeleer E, Douet-Guilbert N, Morel F, Le Bris MJ, Basinko A, De Braekeleer M. *ETV6* fusion genes in hematological malignancies: a review. *Leuk Res* 2012;36:945-61.
9. Kertesz N, Samson J, Debacker C, Wu H, Labastie MC. Cloning and characterization of human and mouse SNRK sucrose non-fermenting protein (SNF-1)-related kinases. *Gene* 2002;294:13-24.
10. Block AW, Carroll AJ, Hagemeyer A, Michaux L, van Lom K, Olney HJ, et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. *Genes Chromosomes Cancer* 2002;33:401-12.